Arbutus Biopharma Corp - Company Profile

Powered by

All the data and insights you need on Arbutus Biopharma Corp in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Arbutus Biopharma Corp Strategy Report

  • Understand Arbutus Biopharma Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Arbutus Biopharma Corp: Overview

Select Item

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corp, focuses on the discovery, development, and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection (HBV). Its pipeline includes capsid assembly inhibitors: AB-729, PD-L1 Inhibitor and a HBV RNA destabilizer. The company develops product candidates based on its lipid nanoparticle (LNP) delivery technology. Arbutus Biopharma works in partnership and collaboration with Genevant Sciences Inc, Alnylam Pharmaceuticals Inc, Acrotech Biopharma LLC and Gritstone Oncology. The company operates in the US and Canada. Arbutus Biopharma is headquartered in Warminster, Pennsylvania, the US.

 Gain a 360-degree view of Arbutus Biopharma Corp and make more informed decisions for your business Gain a 360-degree view of Arbutus Biopharma Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 701 Veterans Circle, Warminster, Pennsylvania, 18974
Website www.arbutusbio.com
Telephone 1 267 4690914
No of Employees 73
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ABUS (NASD)
Revenue (2022) $18.1M -53.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -4.9% (2022 vs 2021)
Market Cap* $490.1M
Net Profit Margin (2022) XYZ -125.6% (2022 vs 2021)
* As of and is in US$
View Arbutus Biopharma Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Arbutus Biopharma Corp premium industry data and analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Arbutus Biopharma Corp’s relevant decision makers and contact details.

50+

Pipeline Drugs

Identify which of Arbutus Biopharma Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Clinical Trials

Determine Arbutus Biopharma Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Catalyst Calendar

Proactively evaluate Arbutus Biopharma Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

15+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Arbutus Biopharma Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Pipeline -
AB-729 (RNA Interface)
AB-836 (Capsid Inhibitor)
XYZ
XYZ
XYZ
Understand Arbutus Biopharma Corp portfolio and identify potential areas for collaboration Understand Arbutus Biopharma Corp portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Arbutus Biopharma Corp Silence Therapeutics Plc Assembly Biosciences Inc Adhera Therapeutics Inc Cocrystal Pharma Inc
Headquarters United States of America United Kingdom United States of America United States of America United States of America
City Warminster London South San Francisco Wake Forest Bothell
State/Province Pennsylvania England California North Carolina Washington
No. of Employees 73 116 65 1 12
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Frank Torti, M.D. Chairman Executive Board 2018 44
David C. Hastings Chief Financial Officer Senior Management 2018 61
Mike McElhaugh Chief Operating Officer; President - Interim; Chief Executive Officer - Interim Senior Management 2024 -
Christopher Naftzger Chief Compliance Officer; General Counsel Senior Management 2023 -
Karen Sims Chief Medical Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Arbutus Biopharma Corp key executives to enhance your sales strategy Gain insight into Arbutus Biopharma Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward